Microbiota intestinal y enfermedades cardiovasculares: implicaciones para la salud pública
| Issue | Vol. 10 Núm. 2 (2026): Ciencia y Salud, mayo-agosto |
| DOI | |
| Publicado | ago. 11, 2026 |
|
Estadísticas |
Research and Education Department, Universidad del Valle de Puebla, México.
Experimental Pathology Research Laboratory, Hospital Infantil de México Federico Gómez; Clinical and Environmental Research Laboratory; Escuela Nacional de Ciencias Biológicas, IPN, México.
Resumen
En los últimos años, la microbiota intestinal ha cobrado protagonismo en diversas patologías fisiológicas, especialmente en las enfermedades cardiovasculares (ECV), principal causa de mortalidad a nivel mundial. La interacción entre los metabolitos bacterianos, la inflamación sistémica y los mecanismos reguladores del metabolismo lipídico y la función endotelial ha generado un interés creciente. Esta revisión narrativa sintetiza la evidencia actual sobre la relación entre la microbiota intestinal y el desarrollo/progresión de las ECV, con énfasis en compuestos como el N-óxido de trimetilamina (TMAO) y los ácidos grasos de cadena corta (AGCC), así como el impacto de las intervenciones dietéticas o probióticas. Además, analizamos las implicaciones para la prevención en salud pública, considerando el potencial de la microbiota como biomarcador de riesgo y herramienta de intervención en estrategias poblacionales.
1. Brown JM, Hazen SL. Microbial modulation of cardiovascular disease. Nat Rev Microbiol. 2018;16(3):171-81. https://doi.org/10.1038/nrmicro.2017.149.
2. Jie Z, Xia H, Zhong SL, Feng Q, Li S, Liang S, et al. The gut microbiome in atherosclerotic cardiovascular disease. Nat Commun. 2017;8:845. https://doi.org/10.1038/s41467-017-00900-1
3. Tang WHW, Li DY, Hazen SL. Dietary metabolism, gut microbiota, and acute heart failure. Heart Fail Rev. 2017;22(2):217-24. https://doi.org/10.1038/s41569-018-0108-7
4. Tang WHW, Bäckhed F, Landmesser U, Hazen SL. Intestinal microbiota in cardiovascular health and disease: JACC state-of-the-art review. J Am Coll Cardiol. 2019;73(16):2089-105. https://doi.org/10.1016/j.jacc.2019.03.024
5. Witkowski M, Weeks TL, Hazen SL. Gut microbiota and cardiovascular disease. Circ Res. 2020;127(4):553-70. https://doi.org/10.1161/CIRCRESAHA.120.316242
6. World Health Organization. Cardiovascular diseases (CVDs) [Internet]. Geneva: WHO; 2021. [citado 2025 Ene 15]. Available from: https://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds).
7. Blaser MJ. Antibiotic use and its consequences for the normal microbiome. Science. 2016;352(6285):544-5. https://doi.org/10.1126/science.aad9358
8. Rodrigues Hoffmann A, Proctor LM, Surette MG, Suchodolski JS. The microbiome: The trillions of microorganisms that maintain health and cause disease in humans and companion animals. Vet Pathol. 2016;53(1):10-21. https://doi.org/10.1177/0300985815595517
9. Wang L, Wang S, Zhang Q, He C, Fu C, Wei Q. The role of the gut microbiota in health and cardiovascular diseases. Mol Biomed. 2022;3(1):30. https://doi.org/10.1186/s43556-022-00091-2
10. Valdes AM, Walter J, Segal E, Spector TD. Role of the gut microbiota in nutrition and health. BMJ. 2018;361: k2179. https://doi.org/10.1136/bmj.k2179.
11. Cryan JF, O'Riordan KJ, Sandhu K, Peterson V, Dinan TG. The gut microbiome in neurological disorders. Lancet Neurol. 2020;19(2):179-94. https://doi.org/10.1016/S1474-4422(19)30356-4
12. Sender R, Fuchs S, Milo R. Revised estimates for the number of human and bacteria cells in the body. PLoS Biol. 2016 Aug;14(8): e1002533. https://doi.org/10.1371/journal.pbio.1002533
13. Magne F, Gotteland M, Gauthier L, Zazueta A, Pesoa S, Navarrete P, et al. The Firmicutes/Bacteroidetes ratio: A relevant marker of gut dysbiosis in obese patients. Nutrients. 2020 May;12(5):1474. https://doi.org/10.3390/nu12051474
14. Miele L, Giorgio V, Alberelli MA, De Candia E, Gasbarrini A, Grieco A. Impact of gut microbiota on obesity, diabetes, and cardiovascular disease risk. Curr Cardiol Rep. 2015 Dec;17(12):120. https://doi.org/10.1007/s11886-015-0671-z
15. Sonnenburg, J., Bäckhed, F. Diet–microbiota interactions as moderators of human metabolism. Nature 535, 56–64 (2016). https://doi.org/10.1038/nature18846
16. Sonnenburg ED, Sonnenburg JL. The ancestral and industrialized gut microbiota and implications for human health. Nat Rev Microbiol. 2019 Jun;17(6):383-90. https://doi.org/10.1038/s41579-019-0191-8
17. Thaiss CA, Zmora N, Levy M, Elinav E. The microbiome and innate immunity. Nature. 2016 Jul;535(7610):65-74. https://doi.org/10.1038/nature18847
18. De Filippo C, Cavalieri D, Di Paola M, Ramazzotti M, Poullet JB, Massart S, et al. Impact of diet in shaping gut microbiota revealed by a comparative study in children from Europe and rural Africa. Proc Natl Acad Sci U S A. 2010 Aug;107(33):14691-6. https://doi.org/10.1073/pnas.1005963107
19. Floch MH, Ringel Y, Walker WA, editors. The microbiota in gastrointestinal pathophysiology. London: Elsevier; 2016. p. 227-32. ISBN: 9780128040621.
20. Azzini E, Polito A, Fumagalli A, Intorre F, Venneria E, Durazzo A, et al. Mediterranean diet effect: An Italian picture. Nutr J. 2011;10:125. https://doi.org/10.1186/1475-2891-10-125
21. Chassaing B, Koren O, Goodrich JK, Poole AC, Srinivasan S, Ley RE, et al. Dietary emulsifiers impact the mouse gut microbiota promoting colitis and metabolic syndrome. Nature. 2015 Mar;519(7541):92-6. https://doi.org/10.1038/nature14232
22. Suez J, Korem T, Zeevi D, Zilberman-Schapira G, Thaiss CA, Maza O, et al. Artificial sweeteners induce glucose intolerance by altering the gut microbiota. Nature. 2014 Oct;514(7521):181-6. https://doi.org/10.1038/nature13793
23. Palmer C, Bik EM, DiGiulio DB, Relman DA, Brown PO. Development of the human infant intestinal microbiota. PLoS Biol. 2007 Jul;5(7): e177. https://doi.org/10.1371/journal.pbio.0050177
24. Jakobsson HE, Jernberg C, Andersson AF, Sjölund-Karlsson M, Jansson JK, Engstrand L. Short-term antibiotic treatment has differing long-term impacts on the human throat and gut microbiome. PLoS One. 2010;5(3): e9836. https://doi.org/10.1371/journal.pone.0009836
25. Blaser MJ. Stop the killing of beneficial bacteria. Nature. 2011 Aug;476(7361):393-4. https://doi.org/10.1038/476393a
26. Kundu P, Blacher E, Elinav E, Pettersson S. Our gut microbiome: The evolving inner self. Cell. 2017 Dec;171(7):1481-93. https://doi.org/10.1016/j.cell.2017.11.024
27. Claesson MJ, Cusack S, O'Sullivan O, Greene-Diniz R, de Weerd H, Flannery E, et al. Composition, variability, and temporal stability of the intestinal microbiota of the elderly. Proc Natl Acad Sci U S A. 2011;108 Suppl 1:4586-91. https://doi.org/10.1073/pnas.1000097107
28. Langille MGI, Meehan CJ, Koenig JE, Dhanani AS, Rose RA, Howlett SE, et al. Microbial shifts in the aging mouse gut. Microbiome. 2014;2(1):50. https://doi.org/10.1186/s40168-014-0050-9
29. Claesson MJ, Jeffery IB, Conde S, Power SE, O’Connor EM, Cusack S, et al. Gut microbiota composition correlates with diet and health in the elderly. Nature. 2012 Aug;488(7410):178-84. https://doi.org/10.1038/nature11319
30. Biagi E, Franceschi C, Rampelli S, Severgnini M, Ostan R, Turroni S, et al. Gut microbiota and extreme longevity. Curr Biol. 2016 Jun;26(11):1480-5. https://doi.org/10.1016/j.cub.2016.04.016
31. Moya A, Ferrer M. Functional redundancy-induced stability of gut microbiota subjected to disturbance. Trends Microbiol. 2016 May;24(5):402-13. https://doi.org/10.1016/j.tim.2016.02.002
32. Faith JJ, Guruge JL, Charbonneau M, Subramanian S, Seedorf H, Goodman AL, et al. The long-term stability of the human gut microbiota. Science. 2013;341(6141):1237439. https://doi.org/10.1126/science.1237439
33. Buttó LF, Schaubeck M, Haller D. Mechanisms of microbe-host interaction in Crohn’s disease: Dysbiosis vs. pathobiont selection. Front Immunol. 2015;6:555. https://doi.org/10.3389/fimmu.2015.00555
34. Gevers D, Kugathasan S, Denson LA, Vazquez-Baeza Y, Van Treuren W, Ren B, et al. The treatment-naive microbiome in new-onset Crohn's disease. Cell Host Microbe. 2014 Mar;15(3):382-92. https://doi.org/10.1016/j.chom.2014.02.005
35. Jostins L, Ripke S, Weersma RK, Duerr RH, McGovern DP, Hui KY, et al. Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature. 2012 Nov;491(7422):119-24. https://doi.org/10.1038/nature11582
36. Schaubeck M, Clavel T, Calasan J, Lagkouvardos I, Haange SB, Jehmlich N, et al. Dysbiotic gut microbiota causes transmissible Crohn's disease-like ileitis independent of failure in antimicrobial defence. Gut. 2016;65(2):225-37. https://doi.org/10.1136/gutjnl-2015-309333
37. Kamada N, Chen GY, Inohara N, Núñez G. Control of pathogens and pathobionts by the gut microbiota. Nat Immunol. 2013;14(7):685-90. https://doi.org/10.1038/ni.2608
38. Druml W. Intestinal cross-talk: The gut as motor of multiple organ failure. Med Klin Intensivmed Notfmed. 2018;113(6):470-7. https://doi.org/10.1007/s00063-018-0475-1
39. Andersen K, Kesper MS, Marschner JA, Konrad L, Ryu M, Kumar Vr S, et al. Intestinal dysbiosis, barrier dysfunction, and bacterial translocation account for CKD-related systemic inflammation. J Am Soc Nephrol. 2017;28(1):76-83. https://doi.org/10.1681/ASN.2015111285
40. Santisteban MM, Qi Y, Zubcevic J, Kim S, Yang T, Shenoy V, et al. Hypertension-linked pathophysiological alterations in the gut. Circ Res. 2017;120(2):312-23. https://doi.org/10.1161/CIRCRESAHA.116.309006
41. Zhou X, Li J, Guo J, Geng B, Ji W, Zhao Q, et al. Gut-dependent microbial translocation induces inflammation and cardiovascular events after ST-elevation myocardial infarction. Microbiome. 2018;6(1):66. https://doi.org/10.1186/s40168-018-0441-4
42. Li XS, Obeid S, Klingenberg R, Gencer B, Mach F, Räber L, et al. Gut microbiota-dependent trimethylamine N-oxide in acute coronary syndromes: A prognostic marker for incident cardiovascular events beyond traditional risk factors. Eur Heart J. 2017;38(11):814-24. https://doi.org/10.1093/eurheartj/ehw582
43. Koeth RA, Wang Z, Levison BS, Buffa JA, Org E, Sheehy BT, et al. Intestinal microbiota metabolism of L-carnitine, a nutrient in red meat, promotes atherosclerosis. Nat Med. 2013;19(5):576-85. https://doi.org/10.1038/nm.3145
44. Wang B, Qiu J, Lian J, Yang X, Zhou J. Gut metabolite trimethylamine-N-oxide in atherosclerosis: From mechanism to therapy. Front Cardiovasc Med. 2021;8:723886. https://doi.org/10.3389/fcvm.2021.723886
45. Li X, Liu Y, Yang X, Li C, Song Z. The oral microbiota: Community composition, influencing factors, pathogenesis, and interventions. Front Microbiol. 2022;13:895537. https://doi.org/10.3389/fmicb.2022.895537
46. Heianza Y, Ma W, Manson JE, Rexrode KM, Qi L. Gut Microbiota Metabolites and Risk of Major Adverse Cardiovascular Disease Events and Death: A Systematic Review and Meta-Analysis of Prospective Studies. Circulation. 2021;143(12):1204-12. https://doi.org/10.1161/JAHA.116.004947
47. Wang Z, Roberts AB, Buffa JA, Levison BS, Zhu W, Org E, et al. Non-lethal inhibition of gut microbial trimethylamine production for the treatment of atherosclerosis. J Am Coll Cardiol. 2021;77(18):2300-12. Https://doi.org/10.1016/j.cell.2015.11.055
48. Dinser L, Meisinger C, Amann U, Heier M, Thilo C, Kuch B, et al. Peripheral arterial disease is associated with higher mortality in patients with incident acute myocardial infarction. Eur J Intern Med. 2018;51:46-52. https://doi.org/10.1016/j.ejim.2018.01.007
49. Silva YP, Bernardi A, Frozza RL. The role of short-chain fatty acids from gut microbiota in gut-brain communication. Front Endocrinol. 2020;11:25. https://doi.org/10.3389/fendo.2020.00025
50. Marques FZ, Nelson E, Chu PY, Horlock D, Fiedler A, Ziemann M, et al. High-fiber diet and acetate supplementation change the gut microbiota and prevent the development of hypertension and heart failure in hypertensive mice. Hypertension. 2017;70(3):479-85. https://doi.org/10.1161/HYPERTENSIONAHA.117.08909
51. Pluznick JL, Protzko RJ, Gevorgyan H, Peterlin Z, Sipos A, Han J, et al. Olfactory receptor responding to gut microbiota-derived signals plays a role in renin secretion and blood pressure regulation. Proc Natl Acad Sci U S A. 2013;110(11):4410-5. https://doi.org/10.1073/pnas.1215927110
52. Maruvada P, Leone V, Kaplan LM, Chang EB. The human microbiome and obesity: Moving beyond associations. Cell Host Microbe. 2017;22(5):589-99. https://doi.org/10.1016/j.chom.2017.10.005
53. Sun J, Yuan B, Wu Y, Gong Y, Guo W, Fu S, et al. Sodium butyrate protects N2a cells against Aβ toxicity in vitro. Mediators Inflamm. 2020;2020:7605160. https://doi.org/10.1155/2020/7605160
54. Natarajan A, Zlitni S, Brooks EF, Vance SE, Dahlen A, Hedlin H, et al. Gastrointestinal symptoms and fecal shedding of SARS-CoV-2 RNA suggest prolonged gastrointestinal infection. Med. 2022;3(6):371-87. https://doi.org/10.1016/j.medj.2022.04.001
55. Pasini E, Aquilani R, Testa C, Baiardi P, Angioletti S, Boschi F, et al. Pathogenic gut flora in patients with chronic heart failure. J Clin Med. 2020;9(3):1-15. https://doi.org/10.1016/j.jchf.2015.10.009
56. Witkowski M, Weeks TL, Hazen SL. Gut microbiota and cardiovascular disease. Science. 2020;368(6491):577-82. https://doi.org/10.1161/CIRCRESAHA.120.316242
57. Prins FM, Collij V, Groot HE, Björk JR, Swarte JC, Andreu-Sánchez S, et al. The gut microbiome across the cardiovascular risk spectrum. Eur J Prev Cardiol. 2024;31(8):935-44. https://doi.org/10.1093/eurjpc/zwad377
58. Lu Q, Wang Y, Li X, Zhang Y, Zhang H, Wang X, et al. Gut microbiota-derived secondary bile acids, bile acids receptor polymorphisms, and risk of cardiovascular disease in individuals with newly diagnosed type 2 diabetes: A cohort study. Am J Clin Nutr. 2024;119(2):324-32. https://doi.org/10.3389/fimmu.2023.1127743
59. Koh A, De Vadder F, Kovatcheva-Datchary P, Bäckhed F. From dietary fiber to host physiology: short-chain fatty acids as key bacterial metabolites. Cell. 2016;165(6):1332-45. https://doi.org/10.1016/j.cell.2016.05.041
60. Tang WHW, Kitai T, Hazen SL. Gut microbiota in cardiovascular health and disease. Circ Res. 2017;120(7):1183-96. https://doi.org/10.1161/CIRCRESAHA.117.309715
61. Wang Z, Klipfell E, Bennett BJ, Koeth R, Levison BS, Dugar B, et al. Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease. Nature. 2011;472(7341):57-63. https://doi.org/10.1038/nature09922
62. Cani PD, Amar J, Iglesias MA, Poggi M, Knauf C, Bastelica D, et al. Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes. 2007;56(7):1761-72. https://doi.org/10.2337/db06-1491
63. Leclercq S, Matamoros S, Cani PD, Neyrinck AM, Jamar F, Stärkel P, et al. Intestinal permeability, gut-bacterial dysbiosis, and behavioral markers of alcohol-dependence severity. Proc Natl Acad Sci USA. 2014;111(42):E4485-93. https://doi.org/10.1073/pnas.1415174111
64. Li X, Deroide N, Mallat Z. The role of the inflammasome in cardiovascular diseases. J Mol Med. 2014;92(4):307-19. https://doi.org/10.1007/s00109-014-1144-3
65. Miura K, Ohnishi H. Role of gut microbiota and Toll-like receptors in nonalcoholic fatty liver disease. World J Gastroenterol. 2014;20(23):7381-91. https://doi.org/10.3748/wjg.v20.i23.7381
66. Gérard P. Gut microbiota and obesity. Cell Mol Life Sci. 2016;73(1):147- https://doi.org/10.1007/s00018-015-2061-5
67. Velagapudi VR, Hezaveh R, Reigstad CS, Gopalacharyulu P, Yetukuri L, Islam S, et al. The gut microbiota modulates host energy and lipid metabolism in mice. J Lipid Res. 2010;51(5):1101-12. https://doi.org/10.1194/jlr.M002774
68. Muralitharan RR, Jama HA, Xie L, Peh A, Snelson M, Marques FZ. Microbial Peer Pressure: The Role of the Gut Microbiota in Hypertension and Its Complications. Hypertension. 2020;76(6):1674 87. https://doi.org/10.1161/HYPERTENSIONAHA.120.14473
69. Dao MC, Everard A, Aron-Wisnewsky J, Sokolovska N, Prifti E, Verger EO, et al. Akkermansia muciniphila and improved metabolic health during a dietary intervention in obesity: relationship with gut microbiome richness and ecology. Gut. 2016;65(3):426-36. https://doi.org/10.1136/gutjnl-2014-308778
70. Turnbaugh PJ, Ley RE, Mahowald MA, Magrini V, Mardis ER, Gordon JI. An obesity-associated gut microbiome with increased capacity for energy harvest. Nature. 2006;444(7122):1027-31. https://doi.org/10.1038/nature05414
71. Janeiro MH, Ramírez MJ, Milagro FI, Martínez JA, Solas M. Implication of trimethylamine N-oxide (TMAO) in disease: Potential biomarker or new therapeutic target. Nutrients. 2018;10(10):1398. https://doi.org/10.3390/nu10101398
72. Ahmad AF, Dwivedi G, O'Gara F, Caparros-Martin J, Ward NC. The gut microbiome and cardiovascular disease: current knowledge and clinical potential. Am J Physiol Heart Circ Physiol. 2019 Nov 1;317(5): H923-H938. https://doi.org/10.1152/ajpheart.00376.2019
73. De Filippis F, Pellegrini N, Vannini L, Jeffery IB, La Storia A, Laghi L, Serrazanetti DI, Di Cagno R, Ferrocino I, Lazzi C, Turroni S, Cocolin L, Brigidi P, Neviani E, Gobbetti M, O'Toole PW, Ercolini D. High-level adherence to a Mediterranean diet beneficially impacts the gut microbiota and associated metabolome. Gut. 2016 Nov; 65(11):1812-1821. https://doi.org/10.1136/gutjnl-2015-309957
74. Khalesi S, Bellissimo N, Vandelanotte C, Williams S, Stanley D, Irwin C. A review of probiotic supplementation in healthy adults: Helpful or hype? Eur J Clin Nutr. 2019;73(1):24-37. https://doi.org/10.1038/s41430-018-0135-9
75. Vrieze A, Van Nood E, Holleman F, Salojärvi J, Kootte RS, Bartelsman JF, Dallinga-Thie GM, Ackermans MT, Serlie MJ, Oozeer R, Derrien M, Druesne A, Van Hylckama Vlieg JE, Bloks VW, Groen AK, Heilig HG, Zoetendal EG, Stroes ES, de Vos WM, Hoekstra JB, Nieuwdorp M. Transfer of intestinal microbiota from lean donors increases insulin sensitivity in individuals with metabolic syndrome. Gastroenterology. 2012 Oct;143(4):913-6. e7. https://doi.org/10.1053/j.gastro.2012.06.031
76. World Health Organization. Healthy diet [Internet]. Geneva: WHO; 2020 – Disponible en: https://www.who.int/news-room/fact-sheets/detail/healthy-diet
77. Valdes AM, Walter J, Segal E, Spector TD. Role of the gut microbiota in nutrition and health. BMJ. 2018;361: k2179. https://doi.org/10.1136/bmj.k2179.
78. Instituto Nacional de Salud Pública. Encuesta Nacional de Salud y Nutrición (ENSANUT 2021) [Internet]. México: INSP; 2021 [citado 2025 Ene 10]. Disponible en: https://ensanut.insp.mx/
79. Instituto Nacional de Estadística y Geografía. Estadísticas de mortalidad en México [Internet]. México: INEGI; 2023 [citado 2024 Ene 25]. Disponible en: https://www.inegi.org.mx/
80. Organización Mundial de la Salud. Enfermedades cardiovasculares: Datos y cifras [Internet]. 2021. Disponible en: https://www.who.int/es/
81. Consejo Nacional de Evaluación de la Política de Desarrollo Social. Medición de la pobreza en México 2022: Resultados nacionales [Internet]. México: CONEVAL; 2022 [citado 2025 Ene 29]. Disponible en: https://www.coneval.org.mx/Medicion/Paginas/PobrezaInicio.aspx
82. Secretaría de Salud. Informe anual del sistema de salud público mexicano [Internet]. [citado 2025 Ene 29]. Disponible en: https://www.gob.mx/salud/.
83. Tang WHW, Li DY, Hazen SL. Dietary metabolism, the gut microbiome, and heart failure. Nat Rev Cardiol. 2019 Mar;16(3):137-154. https://doi.org/10.1038/s41569-018-0108-7
84. Instituto Nacional de Salud Pública. Consumo de alimentos ultraprocesados y su asociación con obesidad en México: Reporte técnico 2022 [Internet]. [citado 2025 Feb 28]. Disponible en: https://www.insp.mx/produccion-editorial/nuevas-publicaciones/consumo-alimentos-ultraprocesados
85. Ministerio de Salud de Chile. Informe de evaluación de la implementación de la Ley de Etiquetado de Alimentos (Ley 20.606) 2021 [Internet]. [citado 2025 Feb 18] Disponible en: https://www.minsal.cl/wp-content/uploads/2021/05/Informe-Evaluacion-Ley-20606-2021.pdf
86. Sonnenburg ED, Sonnenburg JL. Starving our microbial self: the deleterious consequences of a diet deficient in microbiota-accessible carbohydrates. Cell Metab. 2014;20(5):779-86. https://doi.org/10.1016/j.cmet.2014.07.003
87. Perrone P, D'Angelo S. Gut microbiota modulation through Mediterranean diet foods: implications for human health. Nutrients. 2025;17(6):948. https://doi.org/10.3390/nu17060948
88. Martínez I, Stegen JC, Maldonado-Gómez MX, Eren AM, Siba PM, Greenhill AR, et al. The gut microbiota of rural Papua New Guineans: composition, diversity patterns, and ecological processes. Cell Rep. 2015 Apr 28;11(4):527-38. https://doi.org/10.1016/j.celrep.2015.03.049
2. Jie Z, Xia H, Zhong SL, Feng Q, Li S, Liang S, et al. The gut microbiome in atherosclerotic cardiovascular disease. Nat Commun. 2017;8:845. https://doi.org/10.1038/s41467-017-00900-1
3. Tang WHW, Li DY, Hazen SL. Dietary metabolism, gut microbiota, and acute heart failure. Heart Fail Rev. 2017;22(2):217-24. https://doi.org/10.1038/s41569-018-0108-7
4. Tang WHW, Bäckhed F, Landmesser U, Hazen SL. Intestinal microbiota in cardiovascular health and disease: JACC state-of-the-art review. J Am Coll Cardiol. 2019;73(16):2089-105. https://doi.org/10.1016/j.jacc.2019.03.024
5. Witkowski M, Weeks TL, Hazen SL. Gut microbiota and cardiovascular disease. Circ Res. 2020;127(4):553-70. https://doi.org/10.1161/CIRCRESAHA.120.316242
6. World Health Organization. Cardiovascular diseases (CVDs) [Internet]. Geneva: WHO; 2021. [citado 2025 Ene 15]. Available from: https://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds).
7. Blaser MJ. Antibiotic use and its consequences for the normal microbiome. Science. 2016;352(6285):544-5. https://doi.org/10.1126/science.aad9358
8. Rodrigues Hoffmann A, Proctor LM, Surette MG, Suchodolski JS. The microbiome: The trillions of microorganisms that maintain health and cause disease in humans and companion animals. Vet Pathol. 2016;53(1):10-21. https://doi.org/10.1177/0300985815595517
9. Wang L, Wang S, Zhang Q, He C, Fu C, Wei Q. The role of the gut microbiota in health and cardiovascular diseases. Mol Biomed. 2022;3(1):30. https://doi.org/10.1186/s43556-022-00091-2
10. Valdes AM, Walter J, Segal E, Spector TD. Role of the gut microbiota in nutrition and health. BMJ. 2018;361: k2179. https://doi.org/10.1136/bmj.k2179.
11. Cryan JF, O'Riordan KJ, Sandhu K, Peterson V, Dinan TG. The gut microbiome in neurological disorders. Lancet Neurol. 2020;19(2):179-94. https://doi.org/10.1016/S1474-4422(19)30356-4
12. Sender R, Fuchs S, Milo R. Revised estimates for the number of human and bacteria cells in the body. PLoS Biol. 2016 Aug;14(8): e1002533. https://doi.org/10.1371/journal.pbio.1002533
13. Magne F, Gotteland M, Gauthier L, Zazueta A, Pesoa S, Navarrete P, et al. The Firmicutes/Bacteroidetes ratio: A relevant marker of gut dysbiosis in obese patients. Nutrients. 2020 May;12(5):1474. https://doi.org/10.3390/nu12051474
14. Miele L, Giorgio V, Alberelli MA, De Candia E, Gasbarrini A, Grieco A. Impact of gut microbiota on obesity, diabetes, and cardiovascular disease risk. Curr Cardiol Rep. 2015 Dec;17(12):120. https://doi.org/10.1007/s11886-015-0671-z
15. Sonnenburg, J., Bäckhed, F. Diet–microbiota interactions as moderators of human metabolism. Nature 535, 56–64 (2016). https://doi.org/10.1038/nature18846
16. Sonnenburg ED, Sonnenburg JL. The ancestral and industrialized gut microbiota and implications for human health. Nat Rev Microbiol. 2019 Jun;17(6):383-90. https://doi.org/10.1038/s41579-019-0191-8
17. Thaiss CA, Zmora N, Levy M, Elinav E. The microbiome and innate immunity. Nature. 2016 Jul;535(7610):65-74. https://doi.org/10.1038/nature18847
18. De Filippo C, Cavalieri D, Di Paola M, Ramazzotti M, Poullet JB, Massart S, et al. Impact of diet in shaping gut microbiota revealed by a comparative study in children from Europe and rural Africa. Proc Natl Acad Sci U S A. 2010 Aug;107(33):14691-6. https://doi.org/10.1073/pnas.1005963107
19. Floch MH, Ringel Y, Walker WA, editors. The microbiota in gastrointestinal pathophysiology. London: Elsevier; 2016. p. 227-32. ISBN: 9780128040621.
20. Azzini E, Polito A, Fumagalli A, Intorre F, Venneria E, Durazzo A, et al. Mediterranean diet effect: An Italian picture. Nutr J. 2011;10:125. https://doi.org/10.1186/1475-2891-10-125
21. Chassaing B, Koren O, Goodrich JK, Poole AC, Srinivasan S, Ley RE, et al. Dietary emulsifiers impact the mouse gut microbiota promoting colitis and metabolic syndrome. Nature. 2015 Mar;519(7541):92-6. https://doi.org/10.1038/nature14232
22. Suez J, Korem T, Zeevi D, Zilberman-Schapira G, Thaiss CA, Maza O, et al. Artificial sweeteners induce glucose intolerance by altering the gut microbiota. Nature. 2014 Oct;514(7521):181-6. https://doi.org/10.1038/nature13793
23. Palmer C, Bik EM, DiGiulio DB, Relman DA, Brown PO. Development of the human infant intestinal microbiota. PLoS Biol. 2007 Jul;5(7): e177. https://doi.org/10.1371/journal.pbio.0050177
24. Jakobsson HE, Jernberg C, Andersson AF, Sjölund-Karlsson M, Jansson JK, Engstrand L. Short-term antibiotic treatment has differing long-term impacts on the human throat and gut microbiome. PLoS One. 2010;5(3): e9836. https://doi.org/10.1371/journal.pone.0009836
25. Blaser MJ. Stop the killing of beneficial bacteria. Nature. 2011 Aug;476(7361):393-4. https://doi.org/10.1038/476393a
26. Kundu P, Blacher E, Elinav E, Pettersson S. Our gut microbiome: The evolving inner self. Cell. 2017 Dec;171(7):1481-93. https://doi.org/10.1016/j.cell.2017.11.024
27. Claesson MJ, Cusack S, O'Sullivan O, Greene-Diniz R, de Weerd H, Flannery E, et al. Composition, variability, and temporal stability of the intestinal microbiota of the elderly. Proc Natl Acad Sci U S A. 2011;108 Suppl 1:4586-91. https://doi.org/10.1073/pnas.1000097107
28. Langille MGI, Meehan CJ, Koenig JE, Dhanani AS, Rose RA, Howlett SE, et al. Microbial shifts in the aging mouse gut. Microbiome. 2014;2(1):50. https://doi.org/10.1186/s40168-014-0050-9
29. Claesson MJ, Jeffery IB, Conde S, Power SE, O’Connor EM, Cusack S, et al. Gut microbiota composition correlates with diet and health in the elderly. Nature. 2012 Aug;488(7410):178-84. https://doi.org/10.1038/nature11319
30. Biagi E, Franceschi C, Rampelli S, Severgnini M, Ostan R, Turroni S, et al. Gut microbiota and extreme longevity. Curr Biol. 2016 Jun;26(11):1480-5. https://doi.org/10.1016/j.cub.2016.04.016
31. Moya A, Ferrer M. Functional redundancy-induced stability of gut microbiota subjected to disturbance. Trends Microbiol. 2016 May;24(5):402-13. https://doi.org/10.1016/j.tim.2016.02.002
32. Faith JJ, Guruge JL, Charbonneau M, Subramanian S, Seedorf H, Goodman AL, et al. The long-term stability of the human gut microbiota. Science. 2013;341(6141):1237439. https://doi.org/10.1126/science.1237439
33. Buttó LF, Schaubeck M, Haller D. Mechanisms of microbe-host interaction in Crohn’s disease: Dysbiosis vs. pathobiont selection. Front Immunol. 2015;6:555. https://doi.org/10.3389/fimmu.2015.00555
34. Gevers D, Kugathasan S, Denson LA, Vazquez-Baeza Y, Van Treuren W, Ren B, et al. The treatment-naive microbiome in new-onset Crohn's disease. Cell Host Microbe. 2014 Mar;15(3):382-92. https://doi.org/10.1016/j.chom.2014.02.005
35. Jostins L, Ripke S, Weersma RK, Duerr RH, McGovern DP, Hui KY, et al. Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature. 2012 Nov;491(7422):119-24. https://doi.org/10.1038/nature11582
36. Schaubeck M, Clavel T, Calasan J, Lagkouvardos I, Haange SB, Jehmlich N, et al. Dysbiotic gut microbiota causes transmissible Crohn's disease-like ileitis independent of failure in antimicrobial defence. Gut. 2016;65(2):225-37. https://doi.org/10.1136/gutjnl-2015-309333
37. Kamada N, Chen GY, Inohara N, Núñez G. Control of pathogens and pathobionts by the gut microbiota. Nat Immunol. 2013;14(7):685-90. https://doi.org/10.1038/ni.2608
38. Druml W. Intestinal cross-talk: The gut as motor of multiple organ failure. Med Klin Intensivmed Notfmed. 2018;113(6):470-7. https://doi.org/10.1007/s00063-018-0475-1
39. Andersen K, Kesper MS, Marschner JA, Konrad L, Ryu M, Kumar Vr S, et al. Intestinal dysbiosis, barrier dysfunction, and bacterial translocation account for CKD-related systemic inflammation. J Am Soc Nephrol. 2017;28(1):76-83. https://doi.org/10.1681/ASN.2015111285
40. Santisteban MM, Qi Y, Zubcevic J, Kim S, Yang T, Shenoy V, et al. Hypertension-linked pathophysiological alterations in the gut. Circ Res. 2017;120(2):312-23. https://doi.org/10.1161/CIRCRESAHA.116.309006
41. Zhou X, Li J, Guo J, Geng B, Ji W, Zhao Q, et al. Gut-dependent microbial translocation induces inflammation and cardiovascular events after ST-elevation myocardial infarction. Microbiome. 2018;6(1):66. https://doi.org/10.1186/s40168-018-0441-4
42. Li XS, Obeid S, Klingenberg R, Gencer B, Mach F, Räber L, et al. Gut microbiota-dependent trimethylamine N-oxide in acute coronary syndromes: A prognostic marker for incident cardiovascular events beyond traditional risk factors. Eur Heart J. 2017;38(11):814-24. https://doi.org/10.1093/eurheartj/ehw582
43. Koeth RA, Wang Z, Levison BS, Buffa JA, Org E, Sheehy BT, et al. Intestinal microbiota metabolism of L-carnitine, a nutrient in red meat, promotes atherosclerosis. Nat Med. 2013;19(5):576-85. https://doi.org/10.1038/nm.3145
44. Wang B, Qiu J, Lian J, Yang X, Zhou J. Gut metabolite trimethylamine-N-oxide in atherosclerosis: From mechanism to therapy. Front Cardiovasc Med. 2021;8:723886. https://doi.org/10.3389/fcvm.2021.723886
45. Li X, Liu Y, Yang X, Li C, Song Z. The oral microbiota: Community composition, influencing factors, pathogenesis, and interventions. Front Microbiol. 2022;13:895537. https://doi.org/10.3389/fmicb.2022.895537
46. Heianza Y, Ma W, Manson JE, Rexrode KM, Qi L. Gut Microbiota Metabolites and Risk of Major Adverse Cardiovascular Disease Events and Death: A Systematic Review and Meta-Analysis of Prospective Studies. Circulation. 2021;143(12):1204-12. https://doi.org/10.1161/JAHA.116.004947
47. Wang Z, Roberts AB, Buffa JA, Levison BS, Zhu W, Org E, et al. Non-lethal inhibition of gut microbial trimethylamine production for the treatment of atherosclerosis. J Am Coll Cardiol. 2021;77(18):2300-12. Https://doi.org/10.1016/j.cell.2015.11.055
48. Dinser L, Meisinger C, Amann U, Heier M, Thilo C, Kuch B, et al. Peripheral arterial disease is associated with higher mortality in patients with incident acute myocardial infarction. Eur J Intern Med. 2018;51:46-52. https://doi.org/10.1016/j.ejim.2018.01.007
49. Silva YP, Bernardi A, Frozza RL. The role of short-chain fatty acids from gut microbiota in gut-brain communication. Front Endocrinol. 2020;11:25. https://doi.org/10.3389/fendo.2020.00025
50. Marques FZ, Nelson E, Chu PY, Horlock D, Fiedler A, Ziemann M, et al. High-fiber diet and acetate supplementation change the gut microbiota and prevent the development of hypertension and heart failure in hypertensive mice. Hypertension. 2017;70(3):479-85. https://doi.org/10.1161/HYPERTENSIONAHA.117.08909
51. Pluznick JL, Protzko RJ, Gevorgyan H, Peterlin Z, Sipos A, Han J, et al. Olfactory receptor responding to gut microbiota-derived signals plays a role in renin secretion and blood pressure regulation. Proc Natl Acad Sci U S A. 2013;110(11):4410-5. https://doi.org/10.1073/pnas.1215927110
52. Maruvada P, Leone V, Kaplan LM, Chang EB. The human microbiome and obesity: Moving beyond associations. Cell Host Microbe. 2017;22(5):589-99. https://doi.org/10.1016/j.chom.2017.10.005
53. Sun J, Yuan B, Wu Y, Gong Y, Guo W, Fu S, et al. Sodium butyrate protects N2a cells against Aβ toxicity in vitro. Mediators Inflamm. 2020;2020:7605160. https://doi.org/10.1155/2020/7605160
54. Natarajan A, Zlitni S, Brooks EF, Vance SE, Dahlen A, Hedlin H, et al. Gastrointestinal symptoms and fecal shedding of SARS-CoV-2 RNA suggest prolonged gastrointestinal infection. Med. 2022;3(6):371-87. https://doi.org/10.1016/j.medj.2022.04.001
55. Pasini E, Aquilani R, Testa C, Baiardi P, Angioletti S, Boschi F, et al. Pathogenic gut flora in patients with chronic heart failure. J Clin Med. 2020;9(3):1-15. https://doi.org/10.1016/j.jchf.2015.10.009
56. Witkowski M, Weeks TL, Hazen SL. Gut microbiota and cardiovascular disease. Science. 2020;368(6491):577-82. https://doi.org/10.1161/CIRCRESAHA.120.316242
57. Prins FM, Collij V, Groot HE, Björk JR, Swarte JC, Andreu-Sánchez S, et al. The gut microbiome across the cardiovascular risk spectrum. Eur J Prev Cardiol. 2024;31(8):935-44. https://doi.org/10.1093/eurjpc/zwad377
58. Lu Q, Wang Y, Li X, Zhang Y, Zhang H, Wang X, et al. Gut microbiota-derived secondary bile acids, bile acids receptor polymorphisms, and risk of cardiovascular disease in individuals with newly diagnosed type 2 diabetes: A cohort study. Am J Clin Nutr. 2024;119(2):324-32. https://doi.org/10.3389/fimmu.2023.1127743
59. Koh A, De Vadder F, Kovatcheva-Datchary P, Bäckhed F. From dietary fiber to host physiology: short-chain fatty acids as key bacterial metabolites. Cell. 2016;165(6):1332-45. https://doi.org/10.1016/j.cell.2016.05.041
60. Tang WHW, Kitai T, Hazen SL. Gut microbiota in cardiovascular health and disease. Circ Res. 2017;120(7):1183-96. https://doi.org/10.1161/CIRCRESAHA.117.309715
61. Wang Z, Klipfell E, Bennett BJ, Koeth R, Levison BS, Dugar B, et al. Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease. Nature. 2011;472(7341):57-63. https://doi.org/10.1038/nature09922
62. Cani PD, Amar J, Iglesias MA, Poggi M, Knauf C, Bastelica D, et al. Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes. 2007;56(7):1761-72. https://doi.org/10.2337/db06-1491
63. Leclercq S, Matamoros S, Cani PD, Neyrinck AM, Jamar F, Stärkel P, et al. Intestinal permeability, gut-bacterial dysbiosis, and behavioral markers of alcohol-dependence severity. Proc Natl Acad Sci USA. 2014;111(42):E4485-93. https://doi.org/10.1073/pnas.1415174111
64. Li X, Deroide N, Mallat Z. The role of the inflammasome in cardiovascular diseases. J Mol Med. 2014;92(4):307-19. https://doi.org/10.1007/s00109-014-1144-3
65. Miura K, Ohnishi H. Role of gut microbiota and Toll-like receptors in nonalcoholic fatty liver disease. World J Gastroenterol. 2014;20(23):7381-91. https://doi.org/10.3748/wjg.v20.i23.7381
66. Gérard P. Gut microbiota and obesity. Cell Mol Life Sci. 2016;73(1):147- https://doi.org/10.1007/s00018-015-2061-5
67. Velagapudi VR, Hezaveh R, Reigstad CS, Gopalacharyulu P, Yetukuri L, Islam S, et al. The gut microbiota modulates host energy and lipid metabolism in mice. J Lipid Res. 2010;51(5):1101-12. https://doi.org/10.1194/jlr.M002774
68. Muralitharan RR, Jama HA, Xie L, Peh A, Snelson M, Marques FZ. Microbial Peer Pressure: The Role of the Gut Microbiota in Hypertension and Its Complications. Hypertension. 2020;76(6):1674 87. https://doi.org/10.1161/HYPERTENSIONAHA.120.14473
69. Dao MC, Everard A, Aron-Wisnewsky J, Sokolovska N, Prifti E, Verger EO, et al. Akkermansia muciniphila and improved metabolic health during a dietary intervention in obesity: relationship with gut microbiome richness and ecology. Gut. 2016;65(3):426-36. https://doi.org/10.1136/gutjnl-2014-308778
70. Turnbaugh PJ, Ley RE, Mahowald MA, Magrini V, Mardis ER, Gordon JI. An obesity-associated gut microbiome with increased capacity for energy harvest. Nature. 2006;444(7122):1027-31. https://doi.org/10.1038/nature05414
71. Janeiro MH, Ramírez MJ, Milagro FI, Martínez JA, Solas M. Implication of trimethylamine N-oxide (TMAO) in disease: Potential biomarker or new therapeutic target. Nutrients. 2018;10(10):1398. https://doi.org/10.3390/nu10101398
72. Ahmad AF, Dwivedi G, O'Gara F, Caparros-Martin J, Ward NC. The gut microbiome and cardiovascular disease: current knowledge and clinical potential. Am J Physiol Heart Circ Physiol. 2019 Nov 1;317(5): H923-H938. https://doi.org/10.1152/ajpheart.00376.2019
73. De Filippis F, Pellegrini N, Vannini L, Jeffery IB, La Storia A, Laghi L, Serrazanetti DI, Di Cagno R, Ferrocino I, Lazzi C, Turroni S, Cocolin L, Brigidi P, Neviani E, Gobbetti M, O'Toole PW, Ercolini D. High-level adherence to a Mediterranean diet beneficially impacts the gut microbiota and associated metabolome. Gut. 2016 Nov; 65(11):1812-1821. https://doi.org/10.1136/gutjnl-2015-309957
74. Khalesi S, Bellissimo N, Vandelanotte C, Williams S, Stanley D, Irwin C. A review of probiotic supplementation in healthy adults: Helpful or hype? Eur J Clin Nutr. 2019;73(1):24-37. https://doi.org/10.1038/s41430-018-0135-9
75. Vrieze A, Van Nood E, Holleman F, Salojärvi J, Kootte RS, Bartelsman JF, Dallinga-Thie GM, Ackermans MT, Serlie MJ, Oozeer R, Derrien M, Druesne A, Van Hylckama Vlieg JE, Bloks VW, Groen AK, Heilig HG, Zoetendal EG, Stroes ES, de Vos WM, Hoekstra JB, Nieuwdorp M. Transfer of intestinal microbiota from lean donors increases insulin sensitivity in individuals with metabolic syndrome. Gastroenterology. 2012 Oct;143(4):913-6. e7. https://doi.org/10.1053/j.gastro.2012.06.031
76. World Health Organization. Healthy diet [Internet]. Geneva: WHO; 2020 – Disponible en: https://www.who.int/news-room/fact-sheets/detail/healthy-diet
77. Valdes AM, Walter J, Segal E, Spector TD. Role of the gut microbiota in nutrition and health. BMJ. 2018;361: k2179. https://doi.org/10.1136/bmj.k2179.
78. Instituto Nacional de Salud Pública. Encuesta Nacional de Salud y Nutrición (ENSANUT 2021) [Internet]. México: INSP; 2021 [citado 2025 Ene 10]. Disponible en: https://ensanut.insp.mx/
79. Instituto Nacional de Estadística y Geografía. Estadísticas de mortalidad en México [Internet]. México: INEGI; 2023 [citado 2024 Ene 25]. Disponible en: https://www.inegi.org.mx/
80. Organización Mundial de la Salud. Enfermedades cardiovasculares: Datos y cifras [Internet]. 2021. Disponible en: https://www.who.int/es/
81. Consejo Nacional de Evaluación de la Política de Desarrollo Social. Medición de la pobreza en México 2022: Resultados nacionales [Internet]. México: CONEVAL; 2022 [citado 2025 Ene 29]. Disponible en: https://www.coneval.org.mx/Medicion/Paginas/PobrezaInicio.aspx
82. Secretaría de Salud. Informe anual del sistema de salud público mexicano [Internet]. [citado 2025 Ene 29]. Disponible en: https://www.gob.mx/salud/.
83. Tang WHW, Li DY, Hazen SL. Dietary metabolism, the gut microbiome, and heart failure. Nat Rev Cardiol. 2019 Mar;16(3):137-154. https://doi.org/10.1038/s41569-018-0108-7
84. Instituto Nacional de Salud Pública. Consumo de alimentos ultraprocesados y su asociación con obesidad en México: Reporte técnico 2022 [Internet]. [citado 2025 Feb 28]. Disponible en: https://www.insp.mx/produccion-editorial/nuevas-publicaciones/consumo-alimentos-ultraprocesados
85. Ministerio de Salud de Chile. Informe de evaluación de la implementación de la Ley de Etiquetado de Alimentos (Ley 20.606) 2021 [Internet]. [citado 2025 Feb 18] Disponible en: https://www.minsal.cl/wp-content/uploads/2021/05/Informe-Evaluacion-Ley-20606-2021.pdf
86. Sonnenburg ED, Sonnenburg JL. Starving our microbial self: the deleterious consequences of a diet deficient in microbiota-accessible carbohydrates. Cell Metab. 2014;20(5):779-86. https://doi.org/10.1016/j.cmet.2014.07.003
87. Perrone P, D'Angelo S. Gut microbiota modulation through Mediterranean diet foods: implications for human health. Nutrients. 2025;17(6):948. https://doi.org/10.3390/nu17060948
88. Martínez I, Stegen JC, Maldonado-Gómez MX, Eren AM, Siba PM, Greenhill AR, et al. The gut microbiota of rural Papua New Guineans: composition, diversity patterns, and ecological processes. Cell Rep. 2015 Apr 28;11(4):527-38. https://doi.org/10.1016/j.celrep.2015.03.049
AGCC
enfermedades cardiovasculares
microbiota intestinal
salud pública
TMAO
- Resumen visto - 0 veces
- PDF (Inglés) descargado - 0 veces
- HTML (Inglés) descargado - 0 veces
- XML (Inglés) descargado - 0 veces
- EPUB (Inglés) descargado - 0 veces
Descargas
Los datos de descarga aún no están disponibles.
Licencia
Copyright
© Mildred Angélica Sauce Guevara, Alvaro Asaf Guerra Martínez, 2026
Afiliaciones
Mildred Angélica Sauce Guevara
Research and Education Department, Universidad del Valle de Puebla, México.
Alvaro Asaf Guerra Martínez
Experimental Pathology Research Laboratory, Hospital Infantil de México Federico Gómez; Clinical and Environmental Research Laboratory; Escuela Nacional de Ciencias Biológicas, IPN, México.
Cómo citar
1.
Microbiota intestinal y enfermedades cardiovasculares: implicaciones para la salud pública. cisa [Internet]. 2026 Aug. 11 [cited 2026 Aug. 12];10(2):103-17. Available from: https://revistas.intec.edu.do/index.php/cisa/article/view/3521
